Regeneron's pozelimab shows positive effect in PNH study [Seeking Alpha]
Akari Therapeutics Plc - American Depositary Shares (AKTX)
US:NASDAQ Investor Relations:
investor.akaritx.com/investor-relations
Company Research
Source: Seeking Alpha
Seeking Alpha Healthcare Regeneron's pozelimab shows positive effect in PNH study Dec. 5, 2019 7:45 AM ET | Regeneron Pharmaceutic... (REGN) Douglas W. House Topline data Phase 2 clinical trial Lactate dehydrogenase (LDH) returned to normal levels at week 8 in participants receiving a weekly 800 mg dose subcutaneously (following an initial IV loading dose). LDH is a biomarker of elevated hemolysis (destruction of red blood cells) which causes PNH symptoms. On the safety front, no serious adverse events were observed. At data cut-off, three treatment-related adverse events were reported in three (50%) patients: headache (n=2), injection site reaction and nausea. One patient received a blood transfusion on day 50 due to an underlying bone marrow problem. Additional data will be submitted for presentation at a future medical conference. The study's estimated primary completion date is April 2021. Pozelimab is a fully human monoclonal antibody designed to block complement factor C5 and
Show less
Read more
Impact Snapshot
Event Time:
AKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKTX alerts
High impacting Akari Therapeutics Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AKTX
News
- Akari Therapeutics Regains Full Nasdaq ComplianceGlobeNewswire
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak BioGlobeNewswire
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. MergerGlobeNewswire